Potential therapeutic implications of gelsolin in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 44, Issue 1, 2015, Pages 13-25

  Ji, Lina ^a   Zhao, Xi ^a   Hua, Zichun ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Amyloid plaque; Amyloid ; Gelsolin; Neurotoxicity

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BINDING PROTEIN; GELSOLIN; TTR PROTEIN; UNCLASSIFIED DRUG; NEUROLEPTIC AGENT;

ALZHEIMER DISEASE; AMYLOID PLAQUE; CEREBROSPINAL FLUID; CYTOPLASM; DISEASE CLEARANCE; DRUG PROTEIN BINDING; HUMAN; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; REVIEW; ANIMAL; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIPSYCHOTIC AGENTS; GELSOLIN; HUMANS; PLAQUE, AMYLOID;

EID: 84920815557     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141548     Document Type: Review

References (111)

1. Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L, Selkoe DJ (1995) The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat Med 1, 1291-1296.
2. Nilsberth C,Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, Naslund J, Lannfelt L (2001) The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 4, 887-893.
3. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, Dumanchin C, Feuillette S, Brice A, Vercelletto M, Dubas F, Frebourg T, Campion D (2006) APP locus duplication causes autosomal dominant earlyonset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38, 24-26.
4. Mori C, Spooner ET,Wisniewsk KE,Wisniewski TM,Yamaguch H, Saido TC, Tolan DR, Selkoe DJ, Lemere CA (2002) Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid 9, 88-102.
5. Smith EE, Greenberg SM (2009) Beta-amyloid, blood vessels, and brain function. Stroke 40, 2601-2606.
6. Cordonnier C, Al-Shahi Salman R,Wardlaw J (2007) Spontaneous brain microbleeds: Systematic review, subgroup analyses and standards for study design and reporting. Brain 130, 1988-2003.
7. Cordonnier C, van der Flier WM, Sluimer JD, Leys D, Barkhof F, Scheltens P (2006) Prevalence and severity of microbleeds in a memory clinic setting. Neurology 66, 1356-1360.
8. Viswanathan A, Greenberg SM (2011) Cerebral amyloid angiopathy in the elderly. Ann Neurol 70, 871-880.
9. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: Evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13, 159-170.
10. Holtzman DM, Herz J, Bu G (2012) Apolipoprotein E and apolipoprotein E receptors: Normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med 2, a006312.
11. Li GH, Arora PD, Chen Y, McCulloch CA, Liu P (2012) Multifunctional roles of gelsolin in health and diseases. Med Res Rev 32, 999-1025.
12. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298, 789-791.
13. Sakono M, Zako T (2010) Amyloid oligomers: Formation and toxicity of A beta oligomers. FEBS J 277, 1348-1358.
14. Mucke L, Selkoe DJ (2012) Neurotoxicity of amyloid betaprotein: Synaptic and network dysfunction. Cold Spring Harb Perspect Med 2, a006338.
15. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101-112.
16. Hayden EY, Teplow DB (2013) Amyloid beta-protein oligomers and Alzheimer's disease. Alzheimers Res Ther 5, 60.
17. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L (2000) High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci 20, 4050-4058.
18. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539.
19. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM,Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14, 837-842.
20. LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 8, 499-509.
21. Wertkin AM, Turner RS, Pleasure SJ, Golde TE, Younkin SG, Trojanowski JQ, Lee VMY (1993) Human neurons derived from a teratocarcinoma cell-line express solely the 695-amino acid amyloid precursor protein and produce intracellular beta-amyloid or A4 peptides. Proc Natl Acad Sci U S A 90, 9513-9517.
22. Martin BL, Schraderfischer G, Busciglio J, Duke M, Paganetti P, Yankner BA (1995) Intracellular accumulation of beta-amyloid in cells expressing the swedish mutant amyloid precursor protein. J Biol Chem 270, 26727-26730.
23. Knobloch M, Konietzko U, Krebs DC, Nitsch RM (2007) Intracellular Abeta and cognitive deficits precede betaamyloid deposition in transgenic arcAbeta mice. Neurobiol Aging 28, 1297-1306.
24. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421.
25. Penke B, Toth AM, Foldi I, Szucs M, Janaky T (2012) Intraneuronal ss-amyloid and its interactions with proteins and subcellular organelles. Electrophoresis 33, 3608-3616.
26. Yang AJ, Chandswangbhuvana D, Margol L, Glabe CG (1998) Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1-42 pathogenesis. J Neurosci Res 52, 691-698.
27. Ditaranto K, Tekirian TL, Yang AJ (2001) Lysosomal membrane damage in soluble Abeta-mediated cell death in Alzheimer's disease. Neurobiol Dis 8, 19-31.
28. Liu RQ, Zhou QH, Ji SR, Zhou Q, Feng D, Wu Y, Sui SF (2010) Membrane localization of beta-amyloid 1-42 in lysosomes: A possible mechanism for lysosome labilization. J Biol Chem 285, 19986-19996.
29. Tseng BP, Green KN, Chan JL, Blurton-Jones M, LaFerla FM (2008) A beta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging 29, 1607-1618.
30. Oh S, Hong HS, Hwang E, Sim HJ, Lee W, Shin SJ, Mook- Jung I (2005) Amyloid peptide attenuates the proteasome activity in neuronal cells. Mech Ageing Dev 126, 1292-1299.
31. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH (2006) Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: Implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15, 1437-1449.
32. Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader JW, Xu HW, Stern D, McKhann G, Yan SD (2005) Mitochondrial Abeta: A potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J 19, 2040-2041.
33. Lai CS, Preisler J, Baum L, Lee DH, Ng HK, Hugon J, So KF, Chang RC (2009) Low molecular weight Abeta induces collapse of endoplasmic reticulum. Mol Cell Neurosci 41, 32-43.
34. Foldi I, Datki ZL, Szabo Z, Bozso Z, Penke B, Janaky T (2011) Proteomic study of the toxic effect of oligomeric Abeta1-42 in situ prepared from 'iso-Abeta1-42'. J Neurochem 117, 691-702.
35. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM (2005) Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45, 675-688.
36. Gong B, Cao Z, Zheng P, Vitolo OV, Liu S, Staniszewski A, Moolman D, Zhang H, Shelanski M, Arancio O (2006) Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell 126, 775-788.
37. De Strooper B, Vassar R, Golde T (2010) The secretases: Enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 6, 99-107.
38. De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ, Goate A, Kopan R (1999) A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 398, 518-522.
39. Schor NF (2011) What the halted phase III gamma-secretase inhibitor trial may (or may not) be telling us. Ann Neurol 69, 237-239.
40. Golde TE, Schneider LS, Koo EH (2011) Anti-abeta therapeutics in Alzheimer's disease: The need for a paradigm shift. Neuron 69, 203-213.
41. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH (2009) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: Arandomized controlled trial. JAMA 302, 2557-2564.
42. Schenk D, Basi GS, Pangalos MN (2012) Treatment strategies targeting amyloid beta-protein. Cold Spring Harb Perspect Med 2, a006387.
43. Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M, Lacombe D, Kong XQ, Aman A, Laurin J, Szarek WA, Tremblay P (2007) Targeting soluble A beta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 28, 537-547.
44. McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MHL, Phinney AL, Darabie AA, Cousins JE, French JE, Lan MF, Chen FS, Wong SSN, Mount HTJ, Fraser PE,Westaway D, St George-Hyslop P (2006) Cyclohexanehexol inhibitors of A beta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 12, 801-808.
45. Townsend M, Cleary JP, Mehta T, Hofmeister J, Lesne S, O'Hare E, Walsh DM, Selkoe DJ (2006) Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol 60, 668-676.
46. Leissring MA (2006) Proteolytic degradation of the amyloid beta-protein: The forgotten side of Alzheimer's disease. Curr Alzheimer Res 3, 431-435.
47. Spencer B, Marr RA, Rockenstein E, Crews L, Adame A, Potkar R, Patrick C, Gage FH, Verma IM, Masliah E (2008) Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice. BMC Neurosci 9, 109.
48. Liu YX, Guan HJ, Klein R, Oddo S, LaFerla FM, Murphy MP, Hersh LB (2009) Peripheral neprilysin reduces brain amyloid in a transgenic mouse model of Alzheimer's disease. J Neurochem 109, 300.
49. Jacobsen JS, Comery TA, Martone RL, Elokdah H, Crandall DL, Oganesian A, Aschmies S, Kirksey Y, Gonzales C, Xu J, Zhou H, Atchison K, Wagner E, Zaleska MM, Das I, Arias RL, Bard J, Riddell D, Gardell SJ, Abou-Gharbia M, Robichaud A, Magolda R, Vlasuk GP, Bjornsson T, Reinhart PH, Pangalos MN (2008) Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. Proc Natl Acad Sci U S A 105, 8754-8759.
50. Cabrol C, Huzarska MA, Dinolfo C, Rodriguez MC, Reinstatler L, Ni J, Yeh LA, Cuny GD, Stein RL, Selkoe DJ, Leissring MA (2009) Small-molecule activators of insulindegrading enzyme discovered through high-throughput compound screening. Plos One 4, e5274.
51. Solomon B, Koppel R, Frankel D, Hanan Aharon E (1997) Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci U S A 94, 4109-4112.
52. Schenk D, Barbour R, DunnW, Gordon G, Grajeda H, Guido T, Hu K, Huang JP, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao ZM, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 400, 173-177.
53. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, GuidoT,HuK, Huang JP, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N,Weiss K,Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6, 916-919.
54. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM (2002) Immunization reverses memory deficits without reducing brain A beta burden in Alzheimer's disease model. Nat Neurosci 5, 452-457.
55. Sigurdsson EM, Knudsen E, Asuni A, Fitzer-Attas C, Sage D, Quartermain D, Goni F, Frangione B, Wisniewski T (2004) An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J Neurosci 24, 6277-6282.
56. Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang LY, Anwyl R, Selkoe DJ, Rowan MJ (2005) Amyloid beta protein immunotherapy neutralizes A beta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11, 556-561.
57. Schenk D (2002) Amyloid-beta immunotherapy for Alzheimer's disease: The end of the beginning. Nat Rev Neurosci 3, 824-828.
58. Farlow MR, Brosch JR (2013) Immunotherapy for Alzheimer's disease. Neurol Clin 31, 869-878.
59. Schwarzman AL, Gregori L,VitekMP, Lyubski S, Strittmatter WJ, Enghilde JJ, Bhasin R, Silverman J,Weisgraber KH, Coyle PK, Zagorski MG, Talafous J, Eisenberg M, Saunders AM, Roses AD, Goldgaber D (1994) Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci U S A 91, 8368-8372.
60. Schwarzman AL, Goldgaber D (1996) Interaction of transthyretin with amyloid beta-protein: Binding and inhibition of amyloid formation. Ciba Found Symp 199, 146-160; discussion 160-164.
61. Li X, Masliah E, Reixach N, Buxbaum JN (2011) Neuronal production of transthyretin in human and murine Alzheimer's disease: Is it protective? J Neurosci 31, 12483-12490.
62. Costa R, Goncalves A, Saraiva MJ, Cardoso I (2008) Transthyretin binding to A-Beta peptide-impact on A-Beta fibrillogenesis and toxicity. FEBS Lett 582, 936-942.
63. Hansson SF, Andreasson U,Wall M, Skoog I, Andreasen N, Wallin A, Zetterberg H, Blennow K (2009) Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. J Alzheimers Dis 16, 389-397.
64. Velayudhan L, Killick R, Hye A, Kinsey A, Guntert A, Lynham S, Ward M, Leung R, Lourdusamy A, To AW, Powell J, Lovestone S (2012) Plasma transthyretin as a candidate marker for Alzheimer's disease. J Alzheimers Dis 28, 369-375.
65. Choi SH, Leight SN, Lee VM, Li T,Wong PC, Johnson JA, Saraiva MJ, Sisodia SS (2007) Accelerated Abeta deposition in APPswe/PS1deltaE9 mice with hemizygous deletions of TTR (transthyretin). J Neurosci 27, 7006-7010.
66. Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, Das P, Golde T, Masliah E, Roberts AR, Bartfai T (2008) Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity. Proc Natl Acad Sci U S A 105, 2681-2686.
67. Li X, Zhang X, Ladiwala AR, Du D, Yadav JK, Tessier PM, Wright PE, Kelly JW, Buxbaum JN (2013) Mechanisms of transthyretin inhibition of beta-amyloid aggregation in vitro. J Neurosci 33, 19423-19433.
68. Fagan AM,Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM (2002) Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis 9, 305-318.
69. Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, Zlokovic B, Smith JD, Ladu MJ, Rostagno A, Frangione B, Ghiso J (2000) Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochem J 348 Pt 2, 359-365.
70. Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM(2005) Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem 280, 43236-43242.
71. Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, Paul SM, Holtzman DM (2008) Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 118, 671-682.
72. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM (2011) Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med 3, 89ra57.
73. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE (2008) ApoE promotes the proteolytic degradation of Abeta. Neuron 58, 681-693.
74. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, Paul SM (2004) Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 10, 719-726.
75. Yin HL, Kwiatkowski DJ, Mole JE, Cole FS (1984) Structure and biosynthesis of cytoplasmic and secreted variants of gelsolin. J Biol Chem 259, 5271-5276.
76. WenDY, Corina K, ChowEP, Miller S, Janmey PA, Pepinsky RB (1996) The plasma and cytoplasmic forms of human gelsolin differ in disulfide structure. Biochemistry 35, 9700-9709.
77. Lee WM, Galbraith RM (1992) Mechanisms of disease - the extracellular actin-scavenger system and actin toxicity. N Engl J Med 326, 1335-1341.
78. Bucki R, Georges PC, Espinassous Q, Funaki M, Pastore JJ, Chaby R, Janmey PA (2005) Inactivation of endotoxin by human plasma gelsolin. Biochemistry 44, 9590-9597.
79. Rothenbach PA, Dahl B, Schwartz JJ, O'Keefe GE, Yamamoto M, Lee WM, Horton JW, Yin HL, Turnage RH (2004) Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. J Appl Physiol 96, 25-31.
80. Christofidou-Solomidou M, Scherpereel A, Solomides CC, Christie JD, Stossel TP, Goelz S, DiNubile MJ (2002) Recombinant plasma gelsolin diminishes the acute inflammatory response to hyperoxia in mice. J Invest Med 50, 54-60.
81. Maury CPJ, Sletten K, Totty N, Kangas H, Liljestrom M (1997) Identification of the circulating amyloid precursor and other gelsolin metabolites in patients with G654A mutation in the gelsolin gene (Finnish familial amyloidosis): Pathogenetic and diagnostic implications. Lab Invest 77, 299-304.
82. Harms C, Bosel J, Lautenschlager M, Harms U, Braun JS, Hortnagl H, Dirnagl U, Kwiatkowski DJ, Fink K, Endres M (2004) Neuronal gelsolin prevents apoptosis by enhancing actin depolymerization. Mol Cell Neurosci 25, 69-82.
83. Qiao HJ, Koya RC, Nakagawa K, Tanaka H, Fujita H, Takimoto M, Kuzumaki N (2005) Inhibition of Alzheimer's amyloid-beta peptide-induced reduction of mitochondrial membrane potential and neurotoxicity by gelsolin. Neurobiol Aging 26, 849-855.
84. Ohtsu M, Sakai N, Fujita H, Kashiwagi M, Gasa S, Shimizu S, Eguchi Y, Tsujimoto Y, Sakiyama Y, Kobayashi K, Kuzumaki N (1997) Inhibition of apoptosis by the actinregulatory protein gelsolin. EMBO J 16, 4650-4656.
85. Yermen B, Tomas A, Halban PA (2007) Pro-survival role of gelsolin in mouse beta-cells. Diabetes 56, 80-87.
86. Meisel A, Harms C, Yildirim F, Bosel J, Kronenberg G, Harms U, Fink KB, Endres M (2006) Inhibition of histone deacetylation protects wild-type but not gelsolin-deficient neurons from oxygen/glucose deprivation. J Neurochem 98, 1019-1031.
87. Leifeld L, Fink K, Debska G, Fielenbach M, Schmitz V, Sauerbruch T, Spengler U (2006) Anti-apoptotic function of gelsolin in Fas antibody-induced liver failure in vivo. Am J Pathol 168, 778-785.
88. Tanaka H, Shirkoohi R, Nakagawa K, Qiao HJ, Fujita H, Okada F, Hamada J, Kuzumaki S, Takimoto M, Kuzumaki N (2006) siRNA gelsolin knockdown induces epithelialmesenchymal transition with a cadherin switch in human mammary epithelial cells. Int J Cancer 118, 1680-1691.
89. Tanaka M, Mullauer L, Ogiso Y, Fujita H, Moriya S, Furuuchi K, Harabayashi T, Shinohara N,Koyanagi T,Kuzumaki N (1995) Gelsolin - a candidate for suppressor of human bladder-cancer. Cancer Res 55, 3228-3232.
90. Sazawa A, Watanabe T, Tanaka M, Haga K, Fujita H, Harabayashi T, Shinohara N, Koyanagi T, Kuzumaki A (2002) Adenovirus mediated gelsolin gene therapy for orthotopic human bladder cancer in nude mice. J Urol 168, 1182-1187.
91. Endres M, Fink K, Zhu JM, Stagliano NE, Bondada V, Geddes JW, Azuma T, Mattson MP, Kwiatkowski DJ, Moskowitz MA (1999) Neuroprotective effects of gelsolin during murine stroke. J Clin Invest 103, 347-354.
92. Yildirim F, Gertz K, Golo K, Harms C, Fink KB, Meisel A, EndresM(2008) Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury. Exp Neurol 210, 531-542.
93. Kothakota S, Azuma T, Reinhard C, Klippel A, Tang J, Chu KT, McGarry TJ, Kirschner MW, Koths K, Kwiatkowski DJ, Williams LT (1997) Caspase-3-generated fragment of gelsolin: Effector of morphological change in apoptosis. Science 278, 294-298.
94. Wolf BB, Goldstein JC, Stennicke HR, Beere H, Amarante- Mendes GP, Salvesen GS, Green DR (1999) Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation. Blood 94, 1683-1692.
95. Calon F, Lim GP, Morihara T, Yang F, Ubeda O, Salem N Jr, Frautschy SA, Cole GM (2005) Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. Eur J Neurosci 22, 617-626.
96. Zhang QH, Li JC, Dong N, Tang LM, Zhu XM, Sheng ZY, YaoYM(2013) Burn injury induces gelsolin expression and cleavage in the brain of mice. Neuroscience 228, 60-72.
97. Guntert A, Campbell J, Saleem M, O'Brien DP, Thompson AJ, Byers HL, Ward MA, Lovestone S (2010) Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. J Alzheimers Dis 21, 585-596.
98. Antequera D, Vargas T, Ugalde C, Spuch C, Molina JA, Ferrer I, Bermejo-Pareja F, CarroE(2009) Cytoplasmic gelsolin increases mitochondrial activity and reduces A beta burden in a mouse model of Alzheimer's disease. Neurobiol Dis 36, 42-50.
99. Ji L, Chauhan A, Wegiel J, Essa MM, Chauhan V (2009) Gelsolin is proteolytically cleaved in the brains of individuals with Alzheimer's disease. J Alzheimers Dis 18, 105-111.
100. Ji L, Chauhan V, Mehta P, Wegiel J, Mehta S, Chauhan A (2010) Relationship between proteolytically cleaved gelsolin and levels of amyloid-beta protein in the brains of Down syndrome subjects. J Alzheimers Dis 22, 609-617.
101. Hellweg T, Hinssen H, EimerW(1993) The Ca(2+)-induced conformational change of gelsolin is located in the carboxylterminal half of the molecule. Biophys J 65, 799-805.
102. Kusano H, Shimizu S, Koya RC, Fujita H, Kamada S, Kuzumaki N, Tsujimoto Y (2000) Human gelsolin prevents apoptosis by inhibiting apoptotic mitochondrial changes via closing VDAC. Oncogene 19, 4807-4814.
103. Ji L, Chauhan A, ChauhanV(2008) Cytoplasmic gelsolin in pheochromocytoma-12 cells forms a complex with amyloid beta-protein. Neuroreport 19, 463-466.
104. Chauhan VP, Ray I, Chauhan A, Wisniewski HM (1999) Binding of gelsolin, a secretory protein, to amyloid betaprotein. Biochem Biophys Res Commun 258, 241-246.
105. Hirko AC, Meyer EM, King MA, Hughes JA (2007) Peripheral transgene expression of plasma gelsolin reduces amyloid in transgenic mouse models of Alzheimer's disease. Mol Ther 15, 1623-1629.
106. Ray I, Chauhan A,Wegiel J, Chauhan VPS (2000) Gelsolin inhibits the fibrillization of amyloid beta-protein, and also defibrillizes its preformed fibrils. Brain Res 853, 344-351.
107. Henriques AG, Oliveira JM, Gomes B, Ruivo R, da Cruz E, Silva EF, da Cruz E, Silva OA (2014) Complexing Aβ prevents the cellular anomalies induced by the peptide alone. J Mol Neurosci 53, 661-668.
108. MatsuokaY, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, Wang LL, Casey E, Lu YF, Shiratori C, Lemere C, Duff K (2003) Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 23, 29-33.
109. Gregory JL, Prada CM, Fine SJ, Garcia-Alloza M, Betensky RA, Arbel-Ornath M, Greenberg SM, Bacskai BJ, Frosch MP (2012) Reducing available soluble beta-amyloid prevents progression of cerebral amyloid angiopathy in transgenic mice. J Neuropathol Exp Neurol 71, 1009-1017.
110. Yang WZ, Chauhan A, Mehta S, Mehta P, Gu F, Chauhan V (2014) TrichostatinAincreases the levels of plasma gelsolin and amyloid beta-protein in a transgenic mouse model of Alzheimer's disease. Life Sci 99, 31-36.
111. Lopez Salon M, Pasquini L, Besio Moreno M, Pasquini JM, Soto E (2003) Relationship between beta-amyloid degradation and the 26S proteasome in neural cells. Exp Neurol 180, 131-143.